The global lentiviral vector market size is calculated at USD 413.21 million in 2025 and is forecasted to reach around USD 1,908.19 million by 2034, accelerating at a CAGR of 18.53% from 2025 to 2034. The North America market size surpassed USD 156.87 million in 2024 and is expanding at a CAGR of 18.66% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Lentiviral Vector Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Lentiviral Vector Market, by Product Type
8.1.1 1st-Generation
8.1.1.1. Market Revenue and Forecast
8.1.2. 2nd-Generation
8.1.2.1. Market Revenue and Forecast
8.1.3. 3rd-Generation
8.1.3.1. Market Revenue and Forecast
9.1. Lentiviral Vector Market, by Indication
9.1.1. HIV
9.1.1.1. Market Revenue and Forecast
9.1.2. Β-Thalassemia
9.1.2.1. Market Revenue and Forecast
9.1.3. X-Linked Adrenoleukodystrophy
9.1.3.1. Market Revenue and Forecast
9.1.4. Metachromatic Leukodystrophy
9.1.4.1. Market Revenue and Forecast
9.1.5. Wiskott-Aldrich Syndrome
9.1.5.1. Market Revenue and Forecast
10.1. Lentiviral Vector Market, by End User
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast
10.1.3. Research Institutes
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product Type
11.1.2. Market Revenue and Forecast, by Indication
11.1.3. Market Revenue and Forecast, by End User
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product Type
11.1.4.2. Market Revenue and Forecast, by Indication
11.1.4.3. Market Revenue and Forecast, by End User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product Type
11.1.5.2. Market Revenue and Forecast, by Indication
11.1.5.3. Market Revenue and Forecast, by End User
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product Type
11.2.2. Market Revenue and Forecast, by Indication
11.2.3. Market Revenue and Forecast, by End User
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product Type
11.2.4.2. Market Revenue and Forecast, by Indication
11.2.4.3. Market Revenue and Forecast, by End User
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product Type
11.2.5.2. Market Revenue and Forecast, by Indication
11.2.5.3. Market Revenue and Forecast, by End User
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product Type
11.2.6.2. Market Revenue and Forecast, by Indication
11.2.6.3. Market Revenue and Forecast, by End User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product Type
11.2.7.2. Market Revenue and Forecast, by Indication
11.2.7.3. Market Revenue and Forecast, by End User
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product Type
11.3.2. Market Revenue and Forecast, by Indication
11.3.3. Market Revenue and Forecast, by End User
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product Type
11.3.4.2. Market Revenue and Forecast, by Indication
11.3.4.3. Market Revenue and Forecast, by End User
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product Type
11.3.5.2. Market Revenue and Forecast, by Indication
11.3.5.3. Market Revenue and Forecast, by End User
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product Type
11.3.6.2. Market Revenue and Forecast, by Indication
11.3.6.3. Market Revenue and Forecast, by End User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product Type
11.3.7.2. Market Revenue and Forecast, by Indication
11.3.7.3. Market Revenue and Forecast, by End User
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product Type
11.4.2. Market Revenue and Forecast, by Indication
11.4.3. Market Revenue and Forecast, by End User
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product Type
11.4.4.2. Market Revenue and Forecast, by Indication
11.4.4.3. Market Revenue and Forecast, by End User
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product Type
11.4.5.2. Market Revenue and Forecast, by Indication
11.4.5.3. Market Revenue and Forecast, by End User
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product Type
11.4.6.2. Market Revenue and Forecast, by Indication
11.4.6.3. Market Revenue and Forecast, by End User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product Type
11.4.7.2. Market Revenue and Forecast, by Indication
11.4.7.3. Market Revenue and Forecast, by End User
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product Type
11.5.2. Market Revenue and Forecast, by Indication
11.5.3. Market Revenue and Forecast, by End User
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product Type
11.5.4.2. Market Revenue and Forecast, by Indication
11.5.4.3. Market Revenue and Forecast, by End User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product Type
11.5.5.2. Market Revenue and Forecast, by Indication
11.5.5.3. Market Revenue and Forecast, by End User
12.1. Cobra Biologics Limited
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Sirion-Biotech GmbH
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck KGaA
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. FinVector Oy
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Oxford Biomedica
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. OriGene Technologies Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Sino Biological Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Cell Biolabs
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Batavia Biosciences B.V.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Lonza
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample